High Risk, High Payoff

In a Nov. 7, 1994, letter, Marvin Cassman, acting director of the National Institute of General Medical Sciences (NIGMS), informed NIGMS grantees that the institute is "making special efforts" to fund applications that contain risky or unorthodox ideas or methods. Specifically, these would be applications that contain ideas that challenge current dogma; include experimental approaches that have inherent or unavoidable elements of ri

Written byKaren Kreeger
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In a Nov. 7, 1994, letter, Marvin Cassman, acting director of the National Institute of General Medical Sciences (NIGMS), informed NIGMS grantees that the institute is "making special efforts" to fund applications that contain risky or unorthodox ideas or methods. Specifically, these would be applications that contain ideas that challenge current dogma; include experimental approaches that have inherent or unavoidable elements of risk; propose experimental models that are not fully developed or whose utility is not adequately shown; and/or are lacking data to establish the feasibility of the proposed ideas.

"A lot of people in the field don't seem to know that about a year ago the institute and our council recommended that we take 5 percent of our competing research dollars and set it aside to support 'risky' research," Cassman says. These types of grants are typically funded for two years for a total of $120,000 in direct costs.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies